

1 **Comprehensive Testing Highlights Racial, Ethnic, and Age Disparities in the COVID-19**  
2 **Outbreak: Epidemiological and Clinical Characteristic of Cases in Utah**

3 Sharia M Ahmed<sup>1</sup> PhD, Rashmee U. Shah<sup>2</sup> MD, Margaret Bale<sup>3</sup> MPH, Jordan B. Peacock<sup>3</sup> BS,  
4 Ben Berger<sup>3</sup> BA, Alyssa Brown<sup>3</sup> BS, Sara Mann<sup>3</sup> BS, William West<sup>3</sup> BS, Valerie Martin<sup>3</sup> BS,  
5 Valerie Fernandez<sup>4</sup>, Sara Grineski<sup>5,6</sup> PhD, Benjamin Brintz<sup>1,7</sup> PhD, Matthew H. Samore<sup>7,8</sup> MD,  
6 Matthew J. Ferrari<sup>9</sup> PhD, Daniel T. Leung<sup>1†</sup> MD, Lindsay T. Keegan<sup>7†\*</sup> PhD  
7

8 <sup>1</sup>University of Utah School of Medicine, Department of Internal Medicine, Division of Infectious  
9 Diseases, Salt Lake City UT

10 <sup>2</sup>University of Utah School of Medicine, Department of Internal Medicine, Division of  
11 Cardiovascular Medicine, Salt Lake City UT

12 <sup>3</sup>University of Utah School of Medicine, Salt Lake City UT

13 <sup>4</sup>University of Utah, Salt Lake City, UT

14 <sup>5</sup>Center for Natural & Technological Hazards, University of Utah, Salt Lake City, UT

15 <sup>6</sup>Department of Sociology, University of Utah, Salt Lake City, UT

16 <sup>7</sup>University of Utah School of Medicine, Department of Internal Medicine, Division of  
17 Epidemiology, Salt Lake City UT

18 <sup>8</sup>Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA

19 <sup>9</sup>The Pennsylvania State University, Department of Biology, State College, PA  
20

21 †These authors contributed equally

22 \*Corresponding author:

23 Lindsay Keegan

24 [lindsay.keegan@utah.edu](mailto:lindsay.keegan@utah.edu)  
25

26

## 27 **Abstract**

28 The United States (US), which is currently the epicenter for the COVID-19 pandemic, is  
29 a country whose demographic composition differs from that of other highly-impacted countries.  
30 US-based descriptions of SARS-CoV-2 infections have, for the most part, focused on patient  
31 populations with severe disease, captured in areas with limited testing capacity. The objective of  
32 this study is to compare characteristics of positive and negative SARS-CoV-2 patients, in a  
33 population primarily comprised of mild and moderate infections, identified from comprehensive  
34 population-level testing. Here, we extracted demographics, comorbidities, and vital signs from  
35 20,088 patients who were tested for SARS-CoV-2 at University of Utah Health clinics, in Salt  
36 Lake County, Utah; and for a subset of tested patients, we performed manual chart review to  
37 examine symptoms and exposure risks. To determine risk factors for testing positive, we used  
38 logistic regression to calculate the odds of testing positive, adjusting for symptoms and prior  
39 exposure. Of the 20,088 individuals, 1,229 (6.1%) tested positive for SARS-CoV-2. We found  
40 that Non-White persons were more likely to test positive compared to non-Hispanic Whites  
41 (adjOR=1.1, 95% CI: 0.8, 1.6), and that this increased risk is more pronounced among Hispanic  
42 or Latino persons (adjOR=2.0, 95% CI: 1.3, 3.1). However, we did not find differences in the  
43 duration of symptoms nor type of symptom presentation between non-Hispanic White and non-  
44 White individuals. We found that risk of hospitalization increases with age (adjOR=6.9 95% CI:  
45 2.1, 22.5 for age 60+ compared to 0-19), and additionally show that younger individuals (aged 0-  
46 19), were underrepresented both in overall rates of testing as well as rates of testing positive. We  
47 did not find major race/ethnic differences in hospitalization rates. In this analysis of  
48 predominantly non-hospitalized individuals tested for SARS-CoV-2, enabled by expansive  
49 testing capacity, we found disparities in both testing and SARS-CoV-2 infection status by  
50 race/ethnicity and by age. Further work on addressing racial and ethnic disparities, particularly  
51 among Hispanic/Latino communities (where SARS-CoV-2 may be spreading more rapidly due  
52 to increased exposure and comparatively reduced testing), will be needed to effectively combat  
53 COVID-19 in the US.

54

## 55 **Introduction**

56 Since its emergence in humans in late 2019, coronavirus disease 2019 (COVID-19) (caused by  
57 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection), has caused a global  
58 pandemic with over 3 million infections and 230,000 deaths. Currently, the United States (US) is  
59 the epicenter with approximately 30% of all global cases<sup>1</sup>. Although the majority of case- and  
60 disease-course descriptions have originated outside of the US<sup>2-5</sup>, emerging data suggests  
61 symptoms, risk from comorbidities, as well as age and racial patterns of COVID-19 may differ in  
62 the US compared to other highly-impacted countries such as China and Italy. The majority of  
63 US-based clinical or epidemiological descriptions of COVID-19 have been among hospitalized  
64 and ICU patients, due to limited testing capacity in much of the US<sup>6-11</sup>. This bias in study  
65 population is potentially masking differences between hospitalized and non-hospitalized SARS-  
66 CoV-2 infections. Furthermore, due to the locations of most outbreaks, most US-based studies  
67 have focused on highly urban, densely populated areas with high levels of SARS-CoV-2  
68 infection and relatively low testing capacity<sup>10-13</sup>.

69

70 Widespread lack of SARS-CoV-2 testing capacity in the US has led to delays in case detection  
71 and isolation, significant under-reporting of cases (particularly those with mild and moderate

72 symptoms), and gross underestimates of the true number of fatalities<sup>13-18</sup>. In contrast, Utah is  
73 one of only two states (as well as Tennessee) that has maintained high per capita testing rates  
74 (testing 188 per 100,000 persons per day) as well as a stable proportion of positive tests  
75 (approximately 5.5% of all tests were positive since 12 March) (Figure 1)<sup>19</sup>. As such, testing in  
76 Utah has not been restricted to the most critical patients, and the majority of SARS-CoV-2 tests  
77 are administered in outpatient settings to community-dwelling, social distancing persons.  
78

79 The objective of this study is to compare demographic characteristics of positive and negative  
80 patients in a population for which testing is more readily available than previously published  
81 cohorts. In this article, we present the clinical, epidemiological, and demographic characteristics  
82 of all persons (hospitalized and community-dwelling) tested for SARS-CoV-2 infection at  
83 University of Utah Health (UHealth) from 10 March to 24 April 2020. UHealth primarily serves  
84 Salt Lake County, a diverse, medium-density, medium-sized metropolitan area of just over 1  
85 million people. Due to the expanded testing capacity for SARS-CoV-2 in Utah, these data  
86 provide an alternative picture of the full spectrum of SARS-CoV-2 epidemiology relative to  
87 studies of hospitalized patients.  
88

## 89 **Methods**

90 All patients tested for SARS-CoV-2 in the UHealth system were eligible for our study. We  
91 developed an electronic, near real-time registry of all patients tested for SARS-CoV-2 at UHealth  
92 prior to 30 April 2020, for a total sample size of 20,088, representing approximately 20% of all  
93 tests conducted in the State of Utah during that time. The registry was built from the hospital  
94 operations dashboards, which contain basic demographics and test results for all patients tested  
95 for SARS-CoV-2. We linked this data with additional data using the Enterprise Data Warehouse  
96 (EDW) at UHealth. The EDW aggregates data from the health system's disparate data collection  
97 systems in support of operations and research. We extracted demographics, International  
98 Classification of Diseases (ICD) billing codes, and vital signs, from the EDW to create the data  
99 set for this project. Demographic characteristics, including age, sex, and race/ethnicity were  
100 collected from all patients on intake for primary care or hospital visits, and via questionnaire for  
101 mobile testing centers. The department that ordered SARS-CoV-2 test was recorded, and data on  
102 comorbidities were collected via billing codes for all SARS-CoV-2 tested patients. While we  
103 were unable to determine if individuals were hospitalized as a result of their SARS-CoV-2  
104 infection, we approximated this by determining if each person tested was hospitalized for any  
105 cause within 14 days of SARS-CoV-2 testing.  
106

107 For each demographic variable, we calculated the odds ratios for testing SARS-COV-2 positive  
108 for a series of variables including race or ethnicity, age, and sex, adjusted for cough, fever,  
109 shortness of breath, and contact with a known SARS-COV-2 cases. Race/ethnicity was measured  
110 by comparing non-Hispanic White persons to non-White persons. Non-white persons included  
111 Hispanic/Latino, Asian, Black or African American, Native Hawaiian or other Pacific Islander,  
112 American Indian/Native Alaskan and other race individuals, as well as those with unknown race  
113 and those who chose not to disclose their race. We also compared Hispanic persons to non-  
114 Hispanic White persons, as they are the largest minority group in Salt Lake County and comprise  
115 19% of the population.  
116

117 We reviewed clinical text collected between 24 hours before and after SARS-CoV-2 testing for a  
118 subset of 2,043 persons tested prior to 31 March 2020 for additional manual chart review. Of the  
119 20,088 total tests performed, 7,113 were performed prior to 31 March 2020. We selected a  
120 random subset, stratified by date, such that we included at least 20% of patients presenting on  
121 each day. This resulted in a sample size of 2043. Data on symptoms were extracted from the  
122 subset of manually reviewed charts. Symptoms were selected based on previous literature of  
123 SARS-CoV-2-positive patients<sup>20</sup>. Epidemiologic risk factors collected from these charts  
124 included history of travel if mentioned, exposure to a SARS-CoV-2-positive person, healthcare  
125 worker status, and smoking status. Symptoms/exposure factors not mentioned in the medical  
126 chart notes were recorded as ‘not mentioned.’ In analysis we assumed “not mentioned”  
127 symptoms were absent. Percentage of present symptoms are seen below (Table 2).

128  
129 In addition to collecting UHealth data, we extracted county-level and state-level data from the  
130 Utah COVID-19 dashboard for comparison<sup>19</sup>.

131  
132 This study was reviewed by the University of Utah Institutional Review Board (IRB) and  
133 determined to be exempt.

## 134 135 **Results**

### 136 *Demographic Characteristics of Tested Individuals*

137 Of the 20,088 patients tested for SARS-CoV-2 between 10 March 2020 and 24 April 2020, 1,229  
138 (6.1%) tested positive for SARS-CoV-2. Testing occurred at 10 different types of facilities,  
139 including 18,399 (92%) in outpatient clinics, 279 (1%) at mobile testing sites, 958 (5%) in the  
140 emergency department (ED), 219 (1%) in an acute care facility, and 107 (0.5%) tested in the  
141 intensive care unit (ICU). The proportion of positive tests were similar between facility types  
142 (Table 1).

### 143 144 *Race and Ethnicity*

145 While the racial/ethnic distribution of the population tested at UHealth was broadly similar to the  
146 racial/ethnic distribution of Salt Lake County (Figure 2B), there were still statistical differences  
147 ( $p < 0.001$ ). Discrepancies were especially pronounced for persons identifying as Hispanic or  
148 Latino; Hispanic/Latino persons comprise 19% of the county population but only 10% of all  
149 tested at UHealth. Furthermore, we found that non-White persons were more likely to test  
150 positive compared to non-Hispanic White/Caucasians (adjOR=1.1, 95% CI: 0.8, 1.6), and  
151 Hispanic/Latino persons were more likely to test positive compared to non-Hispanic  
152 White/Caucasian persons (adjOR=2.0, 95% CI: 1.3, 3.1; Table 1, Figure 2). Likewise, when  
153 comparing the location where individuals presented for testing (e.g., ED, outpatient clinic,  
154 mobile testing site), we found variation by race/ethnicity ( $p < 0.001$ ), but Hispanic/Latino persons  
155 were only slightly more likely to be tested in the ED compared to non-Hispanic White/Caucasian  
156 (6.3% versus 4.9%). We did not find a difference in reported symptoms between  
157 Hispanic/Latino and non-Hispanic White/Caucasian persons.

### 158 159 *Age Structure*

160 The population tested at UHealth is not similar to the age structure of Salt Lake County (Figure  
161 3). However, the age distribution of those tested at UHealth is consistent between individuals  
162 testing negative versus positive. Younger individuals (aged 0-19), were underrepresented in

163 overall rates of testing and rates of testing positive (Table 1, Figure 3). Without adjusting for the  
164 underlying age distribution of the county population, we found that persons aged 20-59 had the  
165 highest odds of testing positive compared to those 0-19 years old (adjOR=1.6, 95% CI: 0.7, 3.6,  
166 Table 1).

167  
168 *Sex*

169 Persons who tested positive for SARS-CoV-2 were more likely to be male. Among individuals  
170 who tested positive for SARS-CoV-2, over 56% were male (44% were female), while 44% of  
171 individuals who tested negative were male (56% of female). Excluding individuals for which  
172 gender was unknown or non-binary (11 people), males had 1.4 times the odds of testing SARS-  
173 COV-2 positive compared to females (95% CI: 1.0, 1.9).

174  
175 ***Clinical Characteristics***

176 Among manually extracted charts, 136 (6.7%) individuals tested positive for SARS-CoV-2  
177 between 10 March 2020 and 31 March 2020 (Table 2). This was similar to the proportion of  
178 individuals testing positive for SARS-CoV-2 among all those tested 1229 (6.5%).

179  
180 *Clinical symptoms*

181 Persons testing SARS-COV-2-positive and SARS-COV-2-negative had similar vital signs and  
182 rates of cough (89%), but varied in presentation of other symptoms. Symptom profiles were  
183 different in persons who tested SARS-COV-2 positive compared to those who tested SARS-  
184 COV-2 negative (Table 2). The median duration between symptom onset and presentation for  
185 testing was 4 days (IQR=2.1, 7.0) for both SARS-COV-2 positive and SARS-COV-2 negative  
186 persons (Table 2).

187  
188 *Hospitalization rates*

189 Using all-cause hospitalization occurrence within 14 days after testing, we found that 5.1% of  
190 persons tested positive were hospitalized, and 5.1% of persons testing negative were  
191 hospitalized. Rates of hospitalization were similar across racial ethnic groups, with 6% of people  
192 identifying as Black/African American, 5% of people identifying as non-Hispanic  
193 White/Caucasian, and 5% of people identifying as Hispanic/Latino being hospitalized within 14  
194 days of SARS-CoV-2 testing. Those identifying as American Indian and Alaskan Native had  
195 higher rates of 14-day hospitalization (9%), but the sample size was limited.

196  
197 We found that hospitalization differed by age, and older adults had the highest odds of all-cause  
198 hospitalization (adjOR=6.9, 95% CI: 2.1, 22.5 for adults 60+ compared to 0-19-year olds; Table  
199 1, Figure 3). Additionally, we found all-cause hospitalization rates increased with age in both  
200 SARS-COV-2-positive and SARS-COV-2-negative persons (Figure 3d).

201  
202 *Epidemiological Risk Factors*

203 Persons testing SARS-CoV-2 positive were more likely to have known exposure to another  
204 SARS-CoV-2 person or a history of travel (Table 2). Among SARS-COV-2-positive persons,  
205 57% had been in contact with a confirmed SARS-CoV-2 case and 46% had travelled before their  
206 own SARS-CoV-2 testing, compared to 29% and 24% in SARS-COV-2-negative persons,  
207 respectively (Table 2). 9% of SARS-COV-2-positive persons and 11% of SARS-COV-2-  
208 negative persons were healthcare workers (Table 2).



209

## 210 **Conclusions**

211 The high-level of SARS-CoV-2 testing availability in Utah has allowed for a higher proportion  
212 of the outpatient, community dwelling (and usually social distancing) population to be tested.  
213 This expands on previous studies that were limited to more severe or critically-ill patients, as a  
214 result of limited test availability. These data provide insight into the epidemiological and clinical  
215 characteristics of COVID-19 over a much broader range of disease severity, as well as highlight  
216 disparities in COVID-19 response. While the data presented in this study represents only 20% of  
217 the total number of people tested in Utah, based on publicly available state-level data, our  
218 findings are largely representative of the overall state-level outbreak.

219

220 While the racial/ethnic makeup of the population tested for SARS-CoV-2 is broadly similar to  
221 overall county demographics (Figure 2), important discrepancies remain. We found that persons  
222 who identified as non-White had elevated odds of testing positive compared to non-Hispanic  
223 White/Caucasians (adjOR=1.1, 95% CI: 0.8, 1.6). The discrepancy was especially pronounced  
224 for persons identifying as Hispanic or Latino, who had 2.0 times the odds (95% CI: 1.3, 3.1) of  
225 testing SARS-CoV-2 positive compared to those who identified as non-Hispanic White (Figure  
226 2). Though our study is limited to those within a single health system, our results are  
227 representative to those of the county and the state as a whole. For example, Hispanics make up  
228 10% of our tested population, and 22% of those testing positive, which is broadly consistent with  
229 state-level data in which Hispanics make up 14.2% of the population and 36.6% of those testing  
230 positive <sup>19</sup>.

231

232 There are likely several factors that contribute to the disparities in test-positive rate <sup>21</sup>.  
233 Hispanic/Latino persons are disproportionately employed as essential workers, which increases  
234 exposure risk. While Hispanics make up 17.6% of the US workforce, they comprise 25% of  
235 service occupations <sup>22</sup>. This increased employment exposure is likely compounded by the lack of  
236 paid sick leave, as Hispanic workers have lower rates of access to sick leave than do White  
237 workers <sup>23</sup>. Workers without paid sick leave are likely to continue working even while sick,  
238 leading to increased exposure to co-workers and family-members. Another compounding factor  
239 is the decreased ability for public health personnel to conduct contact tracing within minority  
240 communities due to historical and current political instances leading to lack of trust between  
241 minority communities and government bodies <sup>24-29</sup>. It is also the case that Hispanic workers may  
242 be less able to stop working and stay home due to low incomes. Hispanic households in Salt  
243 Lake County make \$56,498/year as compared to \$82,026 among non-Hispanic White households  
244 <sup>30</sup>. Lower incomes also translate into more crowded housing situations, which facilitate virus  
245 transmission. In the US, 10% of Hispanics live in overcrowded conditions <sup>31</sup> and that figure rises  
246 to 33% among older Hispanics in the urban US <sup>32</sup>.

247

248 Persons identifying as non-Hispanic White/Caucasian and Hispanic/Latino were tested at each  
249 facility at approximately equal rates – approximately 5% were tested in the ED, and 90% in  
250 outpatient clinics. Likewise, using symptom presentation or hypoxia (SpO<sub>2</sub> < 90%) as a proxy  
251 for severity, we find no difference between persons identifying as non-Hispanic White/Caucasian  
252 and as Hispanic/Latino. The duration of time from symptom onset to seeking testing was also  
253 similar across races. This suggests racial disparities in SARS-COV-2 burden are not simply due  
254 to Hispanic/Latino persons delaying care until symptoms are critical and presenting to the ED,

255 nor is it as straight forward as preferentially presenting to mobile testing centers. Identifying the  
256 underlying cause of these health disparities is a critical step towards containing SARS-CoV-2.

257  
258 Unlike previous studies<sup>6-11</sup> that focus only on severe or critical patients, we are also able to  
259 identify differential patterns of testing by age. Promisingly, we find most adults (aged 20-79) in  
260 our study have high testing rates (over 100 tests per 10,000 population), which indicates that we  
261 are capturing large numbers of mild and moderate illness. On the other hand, we also show that  
262 testing rates remain lower in children (under 20 years old), and of those under 20 years old who  
263 are tested, rates of SARS-CoV-2 positivity are disproportionately lower. This supports previous  
264 studies which highlight risk of asymptomatic SARS-CoV-2 in younger individuals, as inclusion  
265 in our study was predicated by having at least one symptom (cough, fever, or shortness of breath)  
266 <sup>20</sup>.

267  
268 In addition to differences due to race, we also identified differences due to age. We found the  
269 highest hospitalization rates were among middle-aged SARS-COV-2-positive patients (Figure 3).  
270 This is broadly consistent with Myers et al.<sup>6</sup> who found hospitalized and ICU admitted patients  
271 in California tended to be middle-aged. Like similar studies<sup>8</sup>, we found hospitalization rates  
272 were smallest among younger age individuals (aged 0-19). Indeed, we found persons under 20  
273 years old who tested positive for SARS-CoV-2 were far less likely to be hospitalized than their  
274 peers who were tested for SARS-CoV-2 but tested negative. Compared to other studies, we  
275 found age-adjusted lower hospitalization rates than previously reported among those who test  
276 positive.

277  
278 Given that Utah has the youngest population in the country<sup>33</sup>, a disease that is more likely to be  
279 asymptomatic in younger people is especially salient for the overall state burden and the ability  
280 to control the outbreak as social distancing measures are loosened. Given our finding that  
281 younger individuals are underrepresented in testing due in part to testing criteria, state-level  
282 strategies should be re-examined to consider strategies to target testing of younger age groups  
283 based on geospatial and epidemiological risk factors, regardless of symptomatology.

284  
285 A benefit of expanded testing locations in Salt Lake County was that we were able to assess the  
286 demographic characteristics of testing locations. We found that those tested in outpatient  
287 facilities tended to be younger and that the proportion of persons tested in the ED increased with  
288 age. We found no difference in race/ethnicity by testing location. If testing were to be expanded  
289 to lift symptom requirements in an effort to identify more mild and asymptomatic infections, our  
290 study highlights the benefit of outpatient and mobile facilities to reach underrepresented  
291 demographics.

292  
293 This study offers an important contribution to existing COVID-19 literature, which has been  
294 primarily focused on hospitalized patients. In contrast to previous work, over 90% of people  
295 included in our study were tested in outpatient or community settings. However, our data is  
296 limited to persons who met testing criteria; very few asymptomatic infections are captured in this  
297 study. Further work understanding the demographic and epidemiological characteristics of  
298 asymptomatic infections remains vital to understanding and controlling SARS-CoV-2. By  
299 highlighting critical gaps in testing, particularly among Hispanic/Latino communities, where  
300 SARS-CoV-2 may be spreading more rapidly due to increased exposure and comparatively

301 reduced testing, this study takes a critical first step towards reversing these health disparities. Our  
 302 findings, based largely on those who received testing as outpatients, highlights the potential gaps  
 303 in control of SARS-CoV-2 infection related to age, race, and ethnicity.  
 304

305 *Table 1: Characteristics of SARS-CoV-2-Tested Patients (n=20088)*

	<b>SARS-CoV-2 Positive (N=1229)</b>	<b>SARS-CoV-2 Negative (N=18859)</b>	<b>Adjusted<sup>1</sup> Odds Ratio (95% CI)</b>
<b>Age</b>			
Median – (IQR)	38.4 (27.6 - 51)	39.2 (27.8 - 53.6)	
0-19 – no. (%)	91 (7.4%)	1745 (9.3%)	Reference group
20-59 – no. (%)	994 (81%)	13956 (74%)	1.6 (0.7, 3.6)
60+ – no. (%)	137 (11%)	3154 (17%)	1.4 (0.6, 3.4)
Missing – no. (%)	7 (0.57%)	4 (0.02%)	---
<b>Sex</b>			
Female – no. (%)	545 (44%)	10526 (56%)	Reference group
Male – no. (%)	683 (56%)	8323 (44%)	1.4 (1.0, 1.9)
<b>Race/Ethnicity</b>			
White non-Hispanic – no. (%)	489 (40%)	12662 (67%)	Reference group
Hispanic/Latino – no. (%)	402 (33%)	2402 (12%)	2.0 (1.3, 3.1)
Unknown – no. (%)	182 (15%)	1739 (9.2%)	0.8 (0.4, 1.6)
COMBINED <sup>2</sup>			0.8 (0.4, 1.4)
Black/African American – no. (%)	31 (2.5%)	330 (1.8%)	---
Asian – no. (%)	30 (2.4%)	416 (2.2%)	---
American Indian and Alaska Native – no. (%)	6 (0.49%)	146 (0.77%)	---
Native Hawaiian and Other Pacific Islander – no. (%)	10 (0.8%)	213 (1.1%)	---
Other – no. (%)	44 (3.6%)	498 (2.6%)	---
Refuse – no. (%)	35 (2.9%)	453 (2.4%)	---
<b>BMI</b>			Not Calculated
Median – (IQR)	30.1 (26 - 34.9)	27.6 (23.2 - 32.9)	---
Missing – no. (%)	1161 (95%)	17433 (92%)	---
<b>Comorbidities</b>			Not Calculated
Any comorbidity	134 (11%)	3402 (18%)	---
fluid/electrolyte disorders – no. (%)	7 (0.57%)	221 (1.2%)	---
Renal Failure – no. (%)	8 (0.65%)	172 (0.91%)	---
Alcohol Abuse – no. (%)	5 (0.41%)	207 (1.1%)	---
Chronic blood loss anemia – no. (%)	5 (0.41%)	160 (0.85%)	---
Chronic pulmonary disease – no. (%)	10 (0.81%)	220 (1.2%)	---
Depression – no. (%)	5 (0.41%)	62 (0.33%)	---
Hypertensive renal disease without renal failure – no. (%)	14 (1.2%)	398 (2.1%)	---
Hypertension, uncomplicated – no. (%)	111 (9.0%)	2809 (15%)	---
Obesity – no. (%)	11 (0.90%)	340 (1.8%)	---
Other – no. (%)	12 (0.98%)	600 (3.2%)	---
<b>Pulse Rate</b>			Not Calculated
Median – (IQR)	87 (78 – 99)	85 (75 - 96)	---
Missing – no. (%)	138 (11%)	2068 (11%)	---
<b>Respiratory Rate</b>			Not Calculated
Median – (IQR)	18 (16 - 20)	18 (16 - 20)	---
Missing – no. (%)	1108 (90%)	16552 (88%)	---
<b>SpO2</b>			Not Calculated



Median – (IQR)	96 (94 – 97)	96 (95 - 98)	---
Missing – no. (%)	131 (10.7%)	2054 (11%)	---
<b>Body Temperature (C)</b>			Not Calculated
Median – (IQR)	37.1 (36.7 - 37.6)	37 (36.6 - 37.3)	---
Missing – no. (%)	762 (62%)	11118 (59%)	---
<b>Facility that ordered SARS-CoV-2 test</b>			Not Calculated
Acute care – no. (%)	7 (0.57%)	212 (1.12%)	---
ED – no. (%)	55 (4.48%)	903 (4.79%)	---
External – no. (%)	5 (0.41%)	0 (0%)	---
ICU – no. (%)	6 (0.49%)	101 (0.54%)	---
Inpatient rehab – no. (%)	0 (0%)	10 (0.05%)	---
LND/MNB – no. (%)	0 (0%)	34 (0.18%)	---
Mobile – no. (%)	230 (1.22%)	230 (1.2%)	---
Outpatient Clinics – no. (%)	1095 (89.1%)	17304 (92%)	---
Telemedicine – no. (%)	0 (0%)	25 (0.13%)	---
Other – no. (%)	12 (0.98%)	40 (0.21%)	---

306 <sup>1</sup>Adjusted for cough, fever, shortness of breath, and known contact with SARS-COV-2 case

307 <sup>2</sup>Due to lack of model convergence due to small cell counts, the following race/ethnicity variables were combined  
 308 for odds ratio calculations: Black/African American, Asian, American Indian and Alaska Native, Native Hawaiian  
 309 and Other Pacific Islander, Other, Refuse


310

311 *Table 2: Symptoms in Subset of SARS-CoV-2-tested Patients (n=2043)*

<b>Symptoms</b>	<b>SARS-CoV-2</b>	<b>SARS-CoV-2</b>
	<b>Positive (n=136)</b>	<b>Negative (n=1907)</b>
Cough – no. (%)	121 (89%)	1697 (89%)
Fever – no. (%)	103 (76%)	1229 (64%)
Shortness of breath – no. (%)	68 (50%)	1239 (65%)
Myalgia – no. (%)	57 (42%)	572 (30%)
Headache – no. (%)	50 (37%)	462 (24%)
Lethargy – no. (%)	43 (32%)	496 (26%)
Nasal – no. (%)	44 (32%)	562 (29%)
sore throat – no. (%)	41 (30%)	592 (31%)
Diarrhea – no. (%)	16 (12%)	188 (9.9%)
nausea/vomit – no. (%)	10 (7.4%)	163 (8.6%)
Duration of symptoms – median (IQR)	4.0 (2.3, 7.0)	4.0 (2.0, 7.0)
<b>BEHAVIORS</b>		
Prior exposure – no. (%)	77 (57%)	546 (29%)
Travel – no. (%)	63 (46%)	461 (24%)
Healthcare worker – no. (%)	12 (8.8%)	205 (11%)
Smoker – no. (%)		
never – no. (%)	78 (57%)	869 (46%)
former – no. (%)	5 (3.7%)	164 (8.6%)
current – no. (%)	4 (2.9%)	186 (9.8%)
missing – no. (%)	49 (36%)	688 (36%)


312

313




314  
315  
316  
317  
318  
319  
320

**Figure 1: State-level SARS-CoV-2 testing data in Utah from 04 March to 28 April 2020. Grey bars represent the total number of tests performed each day in Utah and the red bars represent the total number of positive tests, based on the date they were ordered. The black line represents the percent of tests state wide that were positive each day.**



321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340

**Figure 2: Epidemiological characteristics of persons who were tested for SARS-CoV-2 at UHealth by race/ethnicity.** A) Shows 7-day moving average of the percent of tests that were positive by race/ethnicity, each day over the course of the study, for select race and ethnicities. Red, teal, and yellow represent the percent positive for Black or African American, Hispanic, and White or Caucasian persons while black represents the 7-day moving average across all races. B) Shows the percent of persons by each race from the 2018 census estimates for Salt Lake County<sup>34</sup>, the proportion of persons tested by race/ethnicity, as well as the proportion of persons who tested positive by race/ethnicity. C) The log-odds of testing positive by race, compared to White/Caucasian. Adjusted for cough, fever, shortness of breath, and contact with known SARS-COV-2 case. Due to lack of model convergence due to small cell counts, the following race/ethnicity variables were combined for odds ratio calculations: Black/African American, Asian, American Indian and Alaska Native, Native Hawaiian and Other Pacific Islander, Other, Refuse



341  
 342 **Figure 3: Epidemiological characteristics of persons who were tested for SARS-CoV-2 at**  
 343 **UHealth by age.** A) The log-odds of testing positive by age, compared to 0-9 year olds. Adjusted  
 344 for cough, fever, shortness of breath, and contact with known SARS-COV-2 case. B) Shows the  
 345 percent of persons in each age group from the 2018 census estimates for Salt Lake County<sup>34</sup>. C)  
 346 The rate of testing, per 10,000 population, by age for persons testing (light blue) SARS-CoV-2  
 347 positive and (dark blue) SARS-CoV-2 negative. D) The rate of testing, per 10,000 population, by  
 348 age all cause hospitalizations within 14 days of testing for (light blue) SARS-CoV-2 positive and  
 349 (dark blue) SARS-CoV-2 negative.  
 350  
 351

352 **References**

- 353 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real  
354 time. *Lancet Infect Dis.* 2020.
- 355 2. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of  
356 patients infected with SARS-CoV-2 in Singapore. *Jama.* 2020.
- 357 3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus  
358 disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from  
359 the Chinese Center for Disease Control and Prevention. *Jama.* 2020;323(13):1239-1242.
- 360 4. Huang SS, Datta R, Platt R. Risk of acquiring antibiotic-resistant bacteria from prior room  
361 occupants. *Arch Intern Med.* 2006;166(18):1945-1951. doi:10.1001/archinte.166.18.1945
- 362 5. Riccardo F, Ajelli M, Andrianou X, et al. Epidemiological characteristics of COVID-19  
363 cases in Italy and estimates of the reproductive numbers one month into the epidemic.  
364 *medRxiv.* 2020.
- 365 6. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of Hospitalized Adults With  
366 COVID-19 in an Integrated Health Care System in California. *JAMA.* 2020.
- 367 7. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients  
368 with COVID-19 in Washington State. *Jama.* 2020.
- 369 8. Garg S. Hospitalization rates and characteristics of patients hospitalized with laboratory-  
370 confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1--30, 2020.  
371 *MMWR Morb Mortal Wkly Rep.* 2020;69.
- 372 9. Gold JAW. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with  
373 COVID-19—Georgia, March 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69.
- 374 10. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the  
375 Seattle region—case series. *N Engl J Med.* 2020.
- 376 11. Vahidy FS, Nicolas JC, Meeks JR, et al. Racial and Ethnic Disparities in SARS-CoV-2  
377 Pandemic: Analysis of a COVID-19 Observational Registry for a Diverse US  
378 Metropolitan Population. *medRxiv.* 2020.
- 379 12. Project CT. Most recent data. *COVID Track Proj.* 2020. <https://covidtracking.com/data/>.
- 380 13. Bialek S, Bowen V, Chow N, et al. Geographic differences in COVID-19 cases, deaths,  
381 and incidence—United States, February 12--April 7, 2020. 2020.
- 382 14. Padula W V. Why Only Test Symptomatic Patients? Consider Random Screening for  
383 COVID-19. 2020.
- 384 15. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid  
385 dissemination of novel coronavirus (SARS-CoV2). *Science (80- ).* 2020.
- 386 16. Chow EJ, Schwartz NG, Tobolowsky FA, et al. Symptom screening at illness onset of  
387 health care personnel with SARS-CoV-2 infection in King County, Washington. *JAMA.*  
388 2020.
- 389 17. Sharfstein JM, Becker SJ, Mello MM. Diagnostic testing for the novel coronavirus. *Jama.*  
390 2020.
- 391 18. Baggett TP, Keyes H, Sporn N, Gaeta JM. Prevalence of SARS-CoV-2 Infection in  
392 Residents of a Large Homeless Shelter in Boston. *JAMA.* 2020.
- 393 19. coronavirus.utah.gov. Case Counts: coronavirus. Coronavirus.utah.gov.  
394 <https://coronavirus.utah.gov/case-counts/>. Published 2020. Accessed May 1, 2020.
- 395 20. Bialek S, Gierke R, Hughes M, McNamara LA, Pilishvili T, Skoff T. Coronavirus Disease  
396 2019 in Children—United States, February 12--April 2, 2020. *Morb Mortal Wkly Rep.*  
397 2020;69(14):422.



- 398 21. for Disease Control TC, Prevention. COVID-19 in Racial and Ethnic Minority Groups.  
399 2020. [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html)  
400 [minorities.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html). Accessed May 1, 2020.
- 401 22. U.S. Bureau of Labor Statistics. Labor Force Statistics from the Current Population  
402 SurveyCPS CPS Program Links. U.S. Bureau of Labor Statistics.  
403 <https://www.bls.gov/cps/cpsaat11.htm>. Published 2020. Accessed May 1, 2020.
- 404 23. of Labor Statistics USB. Report 1082, Labor force characteristics by race and ethnicity,  
405 2018. 2019. <https://www.bls.gov/opub/reports/race-and-ethnicity/2018/home.html>.  
406 Accessed May 1, 2020.
- 407 24. Munier N, Albarracin J, Boeckelman K. Determinants of rural Latino trust in the federal  
408 government. *Hisp J Behav Sci*. 2015;37(3):420-438.
- 409 25. Armstrong K, Ravenell KL, McMurphy S, Putt M. Racial/ethnic differences in physician  
410 distrust in the United States. *Am J Public Health*. 2007;97(7):1283-1289.
- 411 26. Shoff C, Yang T-C. Untangling the associations among distrust, race, and neighborhood  
412 social environment: A social disorganization perspective. *Soc Sci Med*. 2012;74(9):1342-  
413 1352.
- 414 27. Wilkes R, Wu C. Trust and minority groups. *Oxford Handb Soc Polit Trust*. 2018:231.
- 415 28. Thiede M. Information and access to health care: is there a role for trust? *Soc Sci Med*.  
416 2005;61(7):1452-1462.
- 417 29. Stepanikova I, Mollborn S, Cook KS, Thom DH, Kramer RM. Patients' race, ethnicity,  
418 language, and trust in a physician. *J Health Soc Behav*. 2006;47(4):390-405.
- 419 30. Department SLCH. Healthy Salt Lake, 2020 Demographics. 2020.  
420 [healthysaltlake.org/demographics](https://healthysaltlake.org/demographics). Accessed May 1, 2020.
- 421 31. on Aging NHC. Housing. 2020. <https://www.nhcoa.org/our-focus/housing/>. Accessed  
422 May 1, 2020.
- 423 32. Burr JA, Mutchler JE, Gerst K. Patterns of residential crowding among Hispanics in later  
424 life: Immigration, assimilation, and housing market factors. *Journals Gerontol Ser B*  
425 *Psychol Sci Soc Sci*. 2010;65(6):772-782.
- 426 33. Census US. Median Age in 2010 and 2018 for the United States, Regions, and States.  
427 United States Census Bureau. [https://www.census.gov/newsroom/press-](https://www.census.gov/newsroom/press-kits/2019/detailed-estimates.html)  
428 [kits/2019/detailed-estimates.html](https://www.census.gov/newsroom/press-kits/2019/detailed-estimates.html). Published 2020. Accessed May 1, 2020.
- 429 34. Census TUS. QuickFacts Salt Lake County, Utah; Utah. 2018.  
430 <https://www.census.gov/quickfacts/fact/table/saltlakecountyutah,UT/PST045218>.  
431 Accessed May 1, 2020.
- 432
- 433
- 434

